Details of the Drug Reposition

General Information of This Drug (ID: DM4NWPE)

Drug Name
Brazikumab   DM4NWPE
Drug Type
Monoclonal antibody

Information on Drug Reposition of This Drug

Molecular Interaction Atlas (MIA)
1 Phase 3 Indication(s)
Indication Name Indication ID ICD-11 Status REF
Crohn disease DIS2C5Q8 DD70 Phase 3 [1]
------------------------------------------------------------------------------------
1 Phase 2 Indication(s)
Indication Name Indication ID ICD-11 Status REF
Ulcerative colitis DIS8K27O DD71 Phase 2 [2]
------------------------------------------------------------------------------------

References

1 ClinicalTrials.gov (NCT03961815) An Open-label, Long-term Extension Study of Brazikumab in Participants With Moderately to Severely Active Crohn's Disease (INTREPID OLE). U.S.National Institutes of Health.
2 ClinicalTrials.gov (NCT04277546) A Phase 2 Open-label, Long-term Extension Safety Study of Brazikumab in Participants With Moderately to Severely Active Ulcerative Colitis (EXPEDITION OLE). U.S.National Institutes of Health.